102 Chapter 3 Off study No hydrocortisone addition Identification study Intervention study (RCT) 50 patients Randomisation Dexa + placebo Dexa + placebo Dexa + cortisol Dexa + cortisol Dexa + placebo Dexa + cortisol Dexa + cortisol Questionnaire(s) Time (days) T4 T3 T5 T6 T7 T8 T9 T10 5 5 5 5 16 16 Actigraphy + sleep diary 7 days 7 days 16 T1 No T2 5 days dexamethasone (dexa) Clinically relevant neurobehavioral problems? T2a Bloodsample Questionnaires Study design DexaDays-2 T11 Dexa + placebo 16 ALL MR patients Time (days) 5 2 Figure 1. Study Design DexaDays-2. Schematic study design of the DexaDagen-2 study. See Table 1 (Identification study) and Table 2 (RCT) for the specification of blood samples and questionnaires. Abbreviations: RCT: randomized controlled trial, ALL: acute lymphoblastic leukemia, MR: medium risk, Dexa: dexamethasone
RkJQdWJsaXNoZXIy MTk4NDMw